Talia J. Menzin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Talia J. Menzin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Tiffany S. Woodworth
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA
4 shared publicationsNicole R. Haug
Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts, USA
3 shared publications- Sengwee Toh
Harvard Pilgrim Health Care Institute Department of Population Medicine Boston, MA 02215
3 shared publications - Catherine A. Panozzo
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
2 shared publications Catherine Rogers
Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA
2 shared publicationsEmily C. Welch
Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- 4 July 2023
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 32 (10) , 1178-1183
Switching patterns of immediate‐release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15–64 years in the United States, 2013–2019
Purpose: Immediate‐release forms of generic mixed amphetamine salts (MAS) have been the subject of passive surveillance reports signaling lack of effectiveness. We examined switching patterns that might suggest whether long‐term users of specific MAS are more likely to switch away or switch back after use of the MAS of interest in the FDA's Sentinel Distributed Database.Methods: We required at least 60‐day continuous supply of selected MAS grouped by Abbreviated New Drug Application (ANDA) to describe patterns of switching away from and to generics approved under the ANDAs of interest among individuals ages 15–64 years with attention deficit hyperactivity disorder or narcolepsy during 2013–2019.Results: We observed the greatest number of treatment episodes for ANDA 040422 (n = 525 771), followed by ANDA 202424 (n = 181 693), ANDA 040439 (n = 62 363), ANDA 040440 (n = 21 143), and ANDA 040480 (n = 8792). Of those with switches away from their original ANDA, episodes initiated on generic products under ANDA 040422 (48.6%) and ANDA 202424 (43.0%) were most likely to switch back, while those initiated on generic product under ANDA 040480 were least likely (24.1%). Of those episodes with switches to a generic under an ANDA of interest, about one‐third (range 27.1% to 37.0%) switched back to the same product. These switches back had a median time to switch of about 30 days.Conclusions: These descriptive analyses, although subject to limitations, did not suggest increased switching away or switching back after use of the generics of interest. Continued post‐marketing surveillance is warranted.
- 4 July 2023
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 32 (10) , 1178-1183
Switching patterns of immediate‐release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15–64 years in the United States, 2013–2019
Purpose: Immediate‐release forms of generic mixed amphetamine salts (MAS) have been the subject of passive surveillance reports signaling lack of effectiveness. We examined switching patterns that might suggest whether long‐term users of specific MAS are more likely to switch away or switch back after use of the MAS of interest in the FDA's Sentinel Distributed Database.Methods: We required at least 60‐day continuous supply of selected MAS grouped by Abbreviated New Drug Application (ANDA) to describe patterns of switching away from and to generics approved under the ANDAs of interest among individuals ages 15–64 years with attention deficit hyperactivity disorder or narcolepsy during 2013–2019.Results: We observed the greatest number of treatment episodes for ANDA 040422 (n = 525 771), followed by ANDA 202424 (n = 181 693), ANDA 040439 (n = 62 363), ANDA 040440 (n = 21 143), and ANDA 040480 (n = 8792). Of those with switches away from their original ANDA, episodes initiated on generic products under ANDA 040422 (48.6%) and ANDA 202424 (43.0%) were most likely to switch back, while those initiated on generic product under ANDA 040480 were least likely (24.1%). Of those episodes with switches to a generic under an ANDA of interest, about one‐third (range 27.1% to 37.0%) switched back to the same product. These switches back had a median time to switch of about 30 days.Conclusions: These descriptive analyses, although subject to limitations, did not suggest increased switching away or switching back after use of the generics of interest. Continued post‐marketing surveillance is warranted.
- 13 August 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (10) , 1361-1368
Development of an algorithm to detect methotrexate wrong frequency error using computerized health care data
Purpose: We validated an algorithm to detect frequency errors in computerized healthcare data and estimated the incidence of these errors in an integrated healthcare system.Methods: We applied Sentinel System analytic tools on the electronic health records of Kaiser Permanente, Northern California, January 1, 2010, through May 30, 2015,to identify rheumatoid arthritis (RA) patients with new use of methotrexate (365‐day baseline period). We identified potential methotrexate frequency errors using ICD‐9 code 995.20 (adverse drug event), Current Procedural Terminology (CPT) code 96409 for injection of leucovorin and prescription refill patterns. We performed chart review to confirm the frequency errors, assessed performance for detecting frequency errors, and estimated the incidence of chart‐confirmed errors.Results: The study included 24,529 methotrexate dispensings among 3,668 RA patients. Among these, 722 (3%) had one dispensing and 23,807 (97.1%) had ≥2 dispensings during 1‐year follow‐up period. We flagged 653 (2.7%) with a potential medication error (46 with one dispensing and 607 with ≥2 dispensings). We sampled 94 for chart review, and confirmed three methotrexate errors. All three confirmed frequency errors involved a first methotrexate dispensing followed by injected rescue therapy, leucovorin, (positive predictive value, 60%; 95% confidence interval [CI], 15‐95%). No potential errors were found among patients with ≥2 dispensings. We estimated the frequency error incidence among one methotrexate dispensing to be 0.4% (95%CI, 0.1% to 1.2%).Conclusion: Rescue therapy is a specific indicator of methotrexate overdose among first methotrexate dispensings. This method is generalizable to other medications with serious adverse events treated with antidotes.
- 13 August 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (10) , 1361-1368
Development of an algorithm to detect methotrexate wrong frequency error using computerized health care data
Purpose: We validated an algorithm to detect frequency errors in computerized healthcare data and estimated the incidence of these errors in an integrated healthcare system.Methods: We applied Sentinel System analytic tools on the electronic health records of Kaiser Permanente, Northern California, January 1, 2010, through May 30, 2015,to identify rheumatoid arthritis (RA) patients with new use of methotrexate (365‐day baseline period). We identified potential methotrexate frequency errors using ICD‐9 code 995.20 (adverse drug event), Current Procedural Terminology (CPT) code 96409 for injection of leucovorin and prescription refill patterns. We performed chart review to confirm the frequency errors, assessed performance for detecting frequency errors, and estimated the incidence of chart‐confirmed errors.Results: The study included 24,529 methotrexate dispensings among 3,668 RA patients. Among these, 722 (3%) had one dispensing and 23,807 (97.1%) had ≥2 dispensings during 1‐year follow‐up period. We flagged 653 (2.7%) with a potential medication error (46 with one dispensing and 607 with ≥2 dispensings). We sampled 94 for chart review, and confirmed three methotrexate errors. All three confirmed frequency errors involved a first methotrexate dispensing followed by injected rescue therapy, leucovorin, (positive predictive value, 60%; 95% confidence interval [CI], 15‐95%). No potential errors were found among patients with ≥2 dispensings. We estimated the frequency error incidence among one methotrexate dispensing to be 0.4% (95%CI, 0.1% to 1.2%).Conclusion: Rescue therapy is a specific indicator of methotrexate overdose among first methotrexate dispensings. This method is generalizable to other medications with serious adverse events treated with antidotes.
- 13 November 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (12) , 1416-1421
Overall and cause‐specific mortality in the Sentinel system: A power analysis
Purpose: Mortality data within the Sentinel Death Tables remain generally uncharacterized. Assessment of mortality data within Sentinel will help inform its utility for medical product safety studies.Methods: To determine if Sentinel contains sufficient all‐cause and cause‐specific mortality events to power postmarketing safety studies.We calculated crude rates of all‐cause mortality and suicide and proportional mortality from suicide from 2004 to 2012 in seven Sentinel data partners. Results were stratified by data partner, sex, age group, and calendar year and compared with national estimates from Centers for Disease Control and Prevention Wide‐ranging ONline Data for Epidemiologic Research. We performed sample size estimations for all‐cause mortality and 10 leading causes of death.Results: We observed 479 694 deaths, including 5811 suicides, during 68 million person‐years of follow‐up. Pooled mean death and suicide rates in the data partners were 710 and 8.6 per 100 000 person‐years, respectively (vs 810 and 11.8 nationally). The mean proportional mortality from suicide among the data partners was 1.2%, compared with 1.5% nationally. National trends of decreasing overall mortality and increasing proportional mortality for suicide were reflected within Sentinel. We estimated that detecting hazard ratios of 1.25 and 3 would require 16 442 and 460 exposed patients, respectively, for overall mortality, and 1.3 million and 37 411, respectively, for suicide.Conclusions: This was the first study to investigate mortality data in the Sentinel death tables. We found that all‐cause mortality appeared well powered for use as a safety outcome and cause‐specific mortality outcomes may be adequately powered in certain circumstances. Further investigation into the quality of the Sentinel death data is needed.
- 13 November 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (12) , 1416-1421
Overall and cause‐specific mortality in the Sentinel system: A power analysis
Purpose: Mortality data within the Sentinel Death Tables remain generally uncharacterized. Assessment of mortality data within Sentinel will help inform its utility for medical product safety studies.Methods: To determine if Sentinel contains sufficient all‐cause and cause‐specific mortality events to power postmarketing safety studies.We calculated crude rates of all‐cause mortality and suicide and proportional mortality from suicide from 2004 to 2012 in seven Sentinel data partners. Results were stratified by data partner, sex, age group, and calendar year and compared with national estimates from Centers for Disease Control and Prevention Wide‐ranging ONline Data for Epidemiologic Research. We performed sample size estimations for all‐cause mortality and 10 leading causes of death.Results: We observed 479 694 deaths, including 5811 suicides, during 68 million person‐years of follow‐up. Pooled mean death and suicide rates in the data partners were 710 and 8.6 per 100 000 person‐years, respectively (vs 810 and 11.8 nationally). The mean proportional mortality from suicide among the data partners was 1.2%, compared with 1.5% nationally. National trends of decreasing overall mortality and increasing proportional mortality for suicide were reflected within Sentinel. We estimated that detecting hazard ratios of 1.25 and 3 would require 16 442 and 460 exposed patients, respectively, for overall mortality, and 1.3 million and 37 411, respectively, for suicide.Conclusions: This was the first study to investigate mortality data in the Sentinel death tables. We found that all‐cause mortality appeared well powered for use as a safety outcome and cause‐specific mortality outcomes may be adequately powered in certain circumstances. Further investigation into the quality of the Sentinel death data is needed.
- 26 June 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (8) , 839-847
Early impact of the ICD‐10‐CM transition on selected health outcomes in 13 electronic health care databases in the United States
Purpose: To describe the consistency in the frequency of 5 health outcomes across the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) and Tenth Revision, Clinical Modification (ICD‐10‐CM) eras in the US.Methods: We examined the incidence of 3 acute conditions (acute myocardial infarction [AMI], angioedema, ischemic stroke) and the prevalence of 2 chronic conditions (diabetes, hypertension) during the final 5 years of the ICD‐9‐CM era (January 2010‐September 2015) and the first 15 months of the ICD‐10‐CM era (October 2015‐December 2016) in 13 electronic health care databases in the Sentinel System. For each health outcome reviewed during the ICD‐10‐CM era, we evaluated 4 definitions, including published algorithms derived from other countries, as well as simple‐forward, simple‐backward, and forward‐backward mapping using the General Equivalence Mappings. For acute conditions, we also compared the incidence between April to December 2014 and April to December 2016.Results: The analyses included data from approximately 172 million health plan members. While the incidence or prevalence of AMI and hypertension performed similarly across the 2 eras, the other 3 outcomes did not demonstrate consistent trends for some or all the ICD‐10‐CM definitions assessed.Conclusions: When using data from both the ICD‐9‐CM and ICD‐10‐CM eras, or when using results from ICD‐10‐CM data to compare to results from ICD‐9‐CM data, researchers should test multiple ICD‐10‐CM outcome definitions as part of sensitivity analysis. Ongoing assessment of the impact of ICD‐10‐CM transition on identification of health outcomes in US electronic health care databases should occur as more data accrue.
- 26 June 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (8) , 839-847
Early impact of the ICD‐10‐CM transition on selected health outcomes in 13 electronic health care databases in the United States
Purpose: To describe the consistency in the frequency of 5 health outcomes across the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) and Tenth Revision, Clinical Modification (ICD‐10‐CM) eras in the US.Methods: We examined the incidence of 3 acute conditions (acute myocardial infarction [AMI], angioedema, ischemic stroke) and the prevalence of 2 chronic conditions (diabetes, hypertension) during the final 5 years of the ICD‐9‐CM era (January 2010‐September 2015) and the first 15 months of the ICD‐10‐CM era (October 2015‐December 2016) in 13 electronic health care databases in the Sentinel System. For each health outcome reviewed during the ICD‐10‐CM era, we evaluated 4 definitions, including published algorithms derived from other countries, as well as simple‐forward, simple‐backward, and forward‐backward mapping using the General Equivalence Mappings. For acute conditions, we also compared the incidence between April to December 2014 and April to December 2016.Results: The analyses included data from approximately 172 million health plan members. While the incidence or prevalence of AMI and hypertension performed similarly across the 2 eras, the other 3 outcomes did not demonstrate consistent trends for some or all the ICD‐10‐CM definitions assessed.Conclusions: When using data from both the ICD‐9‐CM and ICD‐10‐CM eras, or when using results from ICD‐10‐CM data to compare to results from ICD‐9‐CM data, researchers should test multiple ICD‐10‐CM outcome definitions as part of sensitivity analysis. Ongoing assessment of the impact of ICD‐10‐CM transition on identification of health outcomes in US electronic health care databases should occur as more data accrue.
- 26 June 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (8) , 829-838
Assessing the impact of the new ICD‐10‐CM coding system on pharmacoepidemiologic studies—An application to the known association between angiotensin‐converting enzyme inhibitors and angioedema
Purpose: To replicate the well‐established association between angiotensin‐converting enzyme inhibitors versus beta blockers and angioedema in the International Classification of Diseases, 10th Revision, Clinical Modification (ICD‐10‐CM) era.Methods: We conducted a retrospective, inception cohort study in a large insurance database formatted to the Sentinel Common Data Model. We defined study periods spanning the ICD‐9‐CM era only, ICD‐10‐CM era only, and ICD‐9‐CM and ICD‐10‐CM era and conducted simple‐forward mapping (SFM), simple‐backward mapping (SBM), and forward‐backward mapping (FBM) referencing the General Equivalence Mappings to translate the outcome (angioedema) and covariates from ICD‐9‐CM to ICD‐10‐CM. We performed propensity score (PS)‐matched and PS‐stratified Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results: In the ICD‐9‐CM and ICD‐10‐CM eras spanning April 1 to September 30 of 2015 and 2016, there were 152 017 and 145 232 angiotensin‐converting enzyme inhibitor initiators and 115 073 and 116 652 beta‐blocker initiators, respectively. The PS‐matched HR was 4.19 (95% CI, 2.82‐6.23) in the ICD‐9‐CM era, 4.37 (2.92‐6.52) in the ICD‐10‐CM era using SFM, and 4.64 (3.05‐7.07) in the ICD‐10‐CM era using SBM and FBM. The PS‐matched HRs from the mixed ICD‐9‐CM and ICD‐10‐CM eras ranged from 3.91 (2.69‐5.68) to 4.35 (3.33‐5.70).Conclusion: The adjusted HRs across different diagnostic coding eras and the use of SFM versus SBM and FBM produced numerically different but clinically similar results. Additional investigations as ICD‐10‐CM data accumulate are warranted.
- 26 June 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (8) , 829-838
Assessing the impact of the new ICD‐10‐CM coding system on pharmacoepidemiologic studies—An application to the known association between angiotensin‐converting enzyme inhibitors and angioedema
Purpose: To replicate the well‐established association between angiotensin‐converting enzyme inhibitors versus beta blockers and angioedema in the International Classification of Diseases, 10th Revision, Clinical Modification (ICD‐10‐CM) era.Methods: We conducted a retrospective, inception cohort study in a large insurance database formatted to the Sentinel Common Data Model. We defined study periods spanning the ICD‐9‐CM era only, ICD‐10‐CM era only, and ICD‐9‐CM and ICD‐10‐CM era and conducted simple‐forward mapping (SFM), simple‐backward mapping (SBM), and forward‐backward mapping (FBM) referencing the General Equivalence Mappings to translate the outcome (angioedema) and covariates from ICD‐9‐CM to ICD‐10‐CM. We performed propensity score (PS)‐matched and PS‐stratified Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results: In the ICD‐9‐CM and ICD‐10‐CM eras spanning April 1 to September 30 of 2015 and 2016, there were 152 017 and 145 232 angiotensin‐converting enzyme inhibitor initiators and 115 073 and 116 652 beta‐blocker initiators, respectively. The PS‐matched HR was 4.19 (95% CI, 2.82‐6.23) in the ICD‐9‐CM era, 4.37 (2.92‐6.52) in the ICD‐10‐CM era using SFM, and 4.64 (3.05‐7.07) in the ICD‐10‐CM era using SBM and FBM. The PS‐matched HRs from the mixed ICD‐9‐CM and ICD‐10‐CM eras ranged from 3.91 (2.69‐5.68) to 4.35 (3.33‐5.70).Conclusion: The adjusted HRs across different diagnostic coding eras and the use of SFM versus SBM and FBM produced numerically different but clinically similar results. Additional investigations as ICD‐10‐CM data accumulate are warranted.